Interactions Between Vitamin D and Breast Cancer

Abstract

Thus far we have recruited 36 breast cancer (BCa) patients of the planned total of 50 subjects. The women were stratified according to their circulating vitamin D status [25(OH)D] and treatment was dependent on their level of 25(OH)D. Of the 36 patients 15 did not receive treatment, 14 received 2000 IU of vitamin D, 5 received 4000 IU and 2 received 6000 IU. The dosing strategy changed during the trial, the current protocol based on circulating levels of vitamin D: > 40 ng/mL no treatment, 30-40 get 2000 IU, 20-30 get 4000 IU, <20 get 6000 IU. We have analyzed the biopsy samples (pre-intervention) and compared results with the surgical specimens (postintervention) to determine whether dietary vitamin D supplements can regulate the gene expression profile in the BCa and normal cells. This has been completed in 20 subjects. The eventual analysis will determine whether vitamin D deficiency is associated with a poor prognosis profile and whether vitamin D intervention converts the profile toward a more normal profile of gene expression, perhaps representing a better prognosis.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2009
Accession Number
ADA518246

Entities

People

  • David Feldman
  • Robert D Carlson

Organizations

  • Stanford University

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Breast Cancer
  • Carrier Proteins
  • Cells
  • Chemistry
  • Department Of Defense
  • Diseases And Disorders
  • Gene Expression
  • Growth Factors
  • Hormones
  • Intervention
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Proteins
  • Vitamin D

Fields of Study

  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.
  • Oncology and Biomarker-Based Cancer Detection.